UNSPSC 51351603: Allylestrenol

This classification denotes a therapeutic progestin with the molecular formula C21H32O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I47VB5DZ8O, chemically known as 19-nor-17-alpha-preg-4-en-17-ol, 21-methylene- but generally known as allylestrenol, which bears US NIH Compound Identifier 9896. European Medicines Agency schedules Allylestrenol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05339MIG.

UNSPSC 51351603 Allylestrenol is a Commodity code covering progestin-based pharmaceutical products that state and local health systems, correctional facilities, and related government health agencies procure through cooperative purchasing vehicles and direct contracts. Recent solicitations under this code reflect state and local demand for generic multi-source pharmaceuticals and over-the-counter products distributed across participating facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, serves as a primary aggregator for this category, leveraging cooperative purchasing to consolidate demand across multiple states and local government health operations. Suppliers must maintain current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance, establish relationships with authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, Morris & Dickson Co., LLC), and support electronic data interchange (EDI) capability and chargeback systems. Pricing structures vary—fixed price, net price formats (NF30, NF60, NF90), or WAC-minus pricing are acceptable—with suppliers typically accepting a 3 percent administrative fee on contract purchases and performance penalties ranging from $200 to $1,500 per violation for reporting delays or onboarding failures.

MMCAP's RFP for Generic Multi Source Pharmaceuticals and OTC Products, posted January 20, 2026, with proposals due March 26, 2026, represents the most recent solicitation under this code and covers activity spanning Minnesota and Oregon. The evaluation weights pricing competitiveness at 75 percent, with the remaining 25 percent split among fixed pricing, administrative compliance, EDI capability, and fee structure agreement. Products must be available in the marketplace by May 15, 2026, with awarded contracts effective July 1, 2026 for new responders (two-year initial term with optional extensions) or aligned with existing expiration dates through June 30, 2028 for incumbents. MMCAP reserves multi-award rights based on therapeutic considerations and member-specific needs. Vendors must carry commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, with all products requiring FDA compliance and minimum six-month shelf life from purchase.